Cytokine induced killer cells-assisted delivery of chlorin e6 mediated self-assembled gold nanoclusters to tumors for imaging and immuno-photodynamic therapy

Xia, Fangfang; Hou, Wenxiu; Liu, Yanlei; Wang, Wentao; Ye, Han; Yang, Meng; Zhi, Xiao; Li, Chenlu; Qi, Daizong; Li, Tianliang; Fuente, Jesús M. de la; Zhang, Chunlei; Song, Jie; Cui, Daxiang

doi:10.1016/j.biomaterials.2018.03.048

Cited by 80 publications

(42 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, residual tumor cells can be destroyed thereby reducing the risk of distant metastasis . Ce6 is a well‐studied photosensitizer (PS) with high 1 O 2 quantum yield, which has been widely exploited for PDT of various solid tumors …”

Section: Methodsmentioning

confidence: 99%

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Zhang

Zhu

et al. 2019

Small

146

114

View full text Add to dashboard Cite

In recent years, stimulating the host immune system to create a promising antitumor immune therapy has been demonstrated to control metastatic tumor growth. [1] Research enthusiasm has been fueled by recent clinical successes in which antibodies were used to block immune inhibitory pathways, specifically the axis between programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1). [2] However, therapeutic antibodies exhibit several disadvantages, such as limited tissue and tumor penetration, very long half-life time, immunogenicity, and costly production. Moreover, the current PD-1/PD-L1 axis-directed monoclonal antibodies lead to a tumor response only in a fraction of cases and tumor types. [3] Therefore, the application of alternative, nonantibody-based agents to inhibit PD-1/ PD-L1 axis is currently a new goal within the field. [4] The development of organic smallmole cule inhibitors is expected to introduce a number of advantages in the field of PD-1/PD-L1 immune checkpoint Targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immunologic checkpoint blockade with monoclonal antibodies has achieved recent clinical success in antitumor therapy. However, therapeutic antibodies exhibit several issues such as limited tumor penetration, immunogenicity, and costly production. Here, Bristol-Myers Squibb nanoparticles (NPs) are prepared using a reprecipitation method. The NPs have advantages including passive targeting, hydrophilic and nontoxic features, and a 100% drug loading rate. BMS-202 is a small-molecule inhibitor of the PD-1/PD-L1 interaction that is developed by BMS. Transfer of BMS-202 NPs to 4T1 tumor-bearing mice results in markedly slower tumor growth to the same degree as treatment with anti-PD-L1 monoclonal antibody (α-PD-L1). Consistently, the combination of Ce6 NPs with BMS-202 NPs or α-PD-L1 in parallel shows more efficacious antitumor and antimetastatic effects, accompanied by enhanced dendritic cell maturation and infiltration of antigen-specific T cells into the tumors. Thus, inhibition rates of primary and distant tumors reach >90%. In addition, BMS-202 NPs are able to attack spreading metastatic lung tumors and offer immune-memory protection to prevent tumor relapse. These results indicate that BMS-202 NPs possess effects similar to α-PD-L1 in the therapies of 4T1 tumors. Therefore, this work reveals the possibility of replacing the antibody used in immunotherapy for tumors with BMS-202 NPs.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Section: Methodsmentioning

confidence: 99%

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Zhang

Zhu

et al. 2019

Small

146

114

View full text Add to dashboard Cite

show abstract

“…In vivo experimental results demonstrated efficient PTT upon NIR irradiation through the killing of GCSCs ( Figure ) . Recently, Xia and co‐workers reported a new strategy using Ce6 (chlorin e6) and gold nanoclusters for the self‐assembly of stable and monodisperse nanoparticles, which were considered as an effective strategy for drug delivery . The cytotoxicity and tumor‐targeting properties associated with CIK (cytokine‐induced killer) cells are thought to be promising in the field of cancer immunotherapy.…”

Section: Antibody‐conjugated Nanomaterialsmentioning

confidence: 99%

Section: Antibody‐conjugated Nanomaterialsmentioning

confidence: 99%

Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics

Kwon

Yan

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Human beings are “machines” that use endogenously produced biomolecules as “components” in signaling and for the maintenance of the body. These biomolecules consist of proteins, nucleic acids, and carbohydrates, which can either be extracted from biological substrates or synthesized by chemical/biochemical methods. These biomolecules have the ability to recognize/interact with other biomolecules that are overexpressed in disease cells. For targeted theranostics, strategies to chemically incorporate these natural biomolecules with advanced materials to treat human diseases by imaging‐guided drug delivery or photodynamic/photothermal therapy are proposed, with improved biocompatibility. Herein, recent research on construction of quantum dots, nanoparticles, and 2D material platforms decorated with antibodies, peptides, nucleic acid aptamers, carbohydrates, and folic acid for targeted diagnosis and treatment are summarized and discussed. In addition, the various strategies required to construct effective functional materials for targeted cancer therapy are highlighted. The hope is that this review can inspire and guide those that are interested in the field of biomedicine to rationally design and develop new target‐based theranostic materials.

show abstract

“…Herein, we integrated anti-angiogenic therapy and phototherapy (PDT and PTT) into one therapeutic strategy by assembling sorafenib (anti-angiogenic agent) and photosensitizer chlorin e6 (Ce6) 47,48 into multifunctional nanoparticles (SC NPs) via the reprecipitation method. The resulting SC NPs presented good water dispersity and passive targeting ability towards tumors based on the EPR effect.…”

Section: Introductionmentioning

confidence: 99%

Carrier-free nano-integrated strategy for synergetic cancer anti-angiogenic therapy and phototherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

Cytokine induced killer cells-assisted delivery of chlorin e6 mediated self-assembled gold nanoclusters to tumors for imaging and immuno-photodynamic therapy

Cited by 80 publications

References 42 publications

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics

Carrier-free nano-integrated strategy for synergetic cancer anti-angiogenic therapy and phototherapy

Contact Info

Product

Resources

About